Show simple item record

dc.contributor.authorChristensen, Hen
dc.contributor.authorTrotter, Carolineen
dc.date.accessioned2017-02-23T16:11:15Z
dc.date.available2017-02-23T16:11:15Z
dc.date.issued2017-01-05en
dc.identifier.issn0264-410X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/262760
dc.description.abstractWe assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against meningococcal disease to children too old to receive the vaccine under the recently introduced infant programme. Offering catch-up vaccination to increasingly older children is less economically attractive because of declining disease burden. We estimate catch-up vaccination of 1year old children could be cost-effective, incremental on the infant programme with a vaccine price of ⩽£8 per dose. Extending vaccination to 2year olds could only be cost-effective (incremental on infant and 1year old catch-up) with a vaccine price of ⩽£3 per dose and was not cost-effective in sensitivity analyses with more conservative vaccine assumptions. Extending catch-up further to 3-4year olds was not cost-effective. Employing the current criteria for assessing vaccines, our models suggest that even with low vaccine prices only catch-up vaccination in 1year old children could be cost-effective, when considered incrementally on the infant programme.
dc.description.sponsorshipThe research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol in partnership with Public Health England (PHE).
dc.languageengen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectcatch-upen
dc.subjectcost-effectivenessen
dc.subjectgroup Ben
dc.subjectmeningococcal diseaseen
dc.subjectvaccinationen
dc.titleModelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in Englanden
dc.typeArticle
prism.endingPage211
prism.issueIdentifier2en
prism.publicationDate2017en
prism.publicationNameVaccineen
prism.startingPage208
prism.volume35en
dc.identifier.doi10.17863/CAM.8050
dcterms.dateAccepted2016-12-01en
rioxxterms.versionofrecord10.1016/j.vaccine.2016.11.076en
rioxxterms.versionAMen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2017-01-05en
dc.contributor.orcidTrotter, Caroline [0000-0003-4000-2708]
dc.identifier.eissn1873-2518
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idPublic Health England (PHE) ()
cam.issuedOnline2016-12-05en
rioxxterms.freetoread.startdate2017-12-05


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International